Gilead Sciences and Be The Match BioTherapies returned for a series B round that boosted the immunotherapy developer's overall funding to $231m.
US-based T-cell immunotherapy developer Tmunity Therapeutics completed a $75m series B round featuring antiviral drug producer Gilead Sciences and cell therapy services provider Be The Match BioTherapies yesterday.
Venture capital firm Andreessen Horowitz led the round, which included its own Cultural Leadership Fund in addition to Westlake Village BioPartners, University of Pennsylvania and BrightEdge, American Cancer Society’s philanthropic impact vehicle.
Tmunity is working on immunotherapies for cancer, infectious and autoimmune diseases and will channel the funding into advancing a pipeline…
